T1	Participants 34 65	patients with advanced melanoma
T2	Participants 1071 1183	187 HLA-A*0201-positive [9.3 months, 95% CI (confidence interval) 7.4-11.5] and 266 HLA-A*0201-negative patients
T3	Participants 325 375	previously treated patients with advanced melanoma
T4	Participants 580 616	class-I HLA-A*0201-positive patients
T5	Participants 932 951	pretreated patients
T6	Participants 1330 1362	137 HLA-A*0201-positive patients
